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Diabetes Mellitus
Worldwide projections suggest that more than 220 million people will have diabetes mellitus by the year 2010, and the majority of these, approximately 213 million, will have type 2 diabetes. 1 Type 2 diabetes mellitus is associated with increased cardiovascular and overall mortality. In fact, type 2 diabetic patients diagnosed before 70 years of age, have only 70% of the life expectancy of non-diabetic people. 2, 3 The long-term relatively specific effects of diabetes include development of retinopathy, nephropathy and neuropathy. 4 People with diabetes are also at increased risk of cardiac, peripheral arterial and cerebrovascular disease.
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Glycated hemoglobin
Glycohaemoglobin is formed by a non-enzymatic interaction between glucose and the amino groups of the valine and lysine residues in haemoglobin. Formation of glycohaemoglobin is irreversible and the level in the red blood cell depends on the blood glucose concentration. Thus, measurement of glycohaemoglobin, which was first introduced in the 1970's, provides a measurement of glycemic control over time, which has been proven to evoke changes in diabetes treatment resulting in improved metabolic control. It is now accepted as a unique and important index in diabetes management reflecting the degree of metabolic control and was a major determinant of the landmark Diabetes Control and Complications Trial (DCCT). 6 Epidemiological data suggest that classic cardiovascular risk factors, such as hypercholesterolemia, hypertension and smoking alone do not account for the excess risk of cardiovascular morbidity and mortality in type 2 diabetes mellitus. Rather, the excess morbidity and mortality is linked to the disease itself. Type-I diabetes is accompanied by long-term micro-and macrovascular complications, the primary causes of morbidity and mortality in these patients. Diabetic nephropathy, as the single most common cause of end-stage renal disease, accounts for more than one-third of all cases. Thus, understanding the pathogenesis and preventing and/or ameliorating these long-term complications have been major goals of research in diabetes mellitus.
The core of the issue is glycemic control. It has long been suspected that high blood glucose is harmful in a variety of ways and that all the complications whether microvascular or macrovascular, were to a larger or lesser extent linked with it. In recent times this has been well established. Amongst the various markers of glycemic control, glycated hemoglobin (GHb) has now been established as the most reliable, though many other proteins are also glycated in the diabetic and non-diabetic states 7 .
The prognostic role of HbA1c is well established and accepted. In the normal 120-day lifespan of the red blood cell, glucose molecules react with hemoglobin, forming glycated hemoglobin. Glucose forms an aldimine linkage with NH2-of valine in the β-chain, undergoing an Amadori rearrangement to form the more stable ketoamine linkage. Glycated hemoglobin has been used primarily to as a marker to identify the average plasma glucose concentration over prolonged periods of time. As the average amount of plasma glucose increases, the fraction of glycated hemoglobin increases in a predictable way. In diabetes mellitus, higher amounts of glycated hemoglobin, indicating poorer control of blood glucose levels, have been associated with cardiovascular disease, nephropathy, and retinopathy. HbA1c reflects average plasma glucose over the previous eight to 12 weeks. 9 It can be performed at any time of the day and does not require any special preparation such as fasting. These properties have made it the preferred test for assessing glycemic control in people with diabetes. More recently, there has been substantial interest in using it as a diagnostic test for diabetes and as a screening test for persons at high risk of diabetes. 10 The types of glycated hemoglobin are shown in Table 1 .
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Due to the inconsistencies in the reported reference range of glycated hemoglobin from different labs, the present study was planned to establish the reference range for glycated hemoglobin (HbA1C) in healthy non-diabetic subjects in our hospital laboratory and compare it with the values reported by standard laboratories. 
METHODS
The study was conducted in the Department of Biochemistry, MMIMSR, Mullana (Ambala, Haryana). Total number of subjects was 50 (25 males, 25 females), aged 30 to 70 years. 2 ml of blood was collected from antecubital vein under aseptic conditions from each subject and put in EDTA vials. Hemolysed blood was estimated for HbA1C by semi-autoanalyzer. 
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RESULTS
In females, the levels were 6.50 ± 0.74 % while in males the levels were 6.27 ± 0.94 %. The overall range in females was 4.8-7.56 % while in males it was 4.2 to 7.56 %. The values were comparable (p>0.05) with those reported by standard laboratories, e.g. Dr. Lal PathLabs (<6 %), Charak diagnostic (4.5-6.3 %) and Mayo Clinic (6.5-7 %).
DISCUSSION
There remain numerous analytical problems associated with glycated hemoglobin measurement, such as the lack of assay standardization and the problems related to its Each method has its own advantages and disadvantages (Table 3) . 13 Methods of GHb assays have primarily evolved around three basic methodologies: 8 (1) Based on difference in ionic charge.
(2) Based on structural characteristics.
(3) Based on chemical reactivity. 
CONCLUSIONS
Our laboratory levels of HbA1C are comparable with the reference range of different laboratories and hence suitable to be used as cut-offs while interpreting the results of patients with diabetes mellitus. It is recommended that each laboratory should establish its own normal range representing its patient population.
